BioSpace News Archive

Enzychem Lifesciences , a clinical-stage biotherapeutics company engaged in the discovery and development of innovative medicines focused on the inflammation pathway, today announced that preclinical research involving their lead compound EC-18 (PLAG), and its activity in gouty arthritis have been published in the peer-reviewed journal

Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced the closing of its previously announced underwritten public offering of common stock.

Hebron Technology Co., Ltd. announced it has closed a previously announced private placement, in which the Company sold to two private investors an aggregate of 1,048,932 Class A common shares, par value $0.001 per share, at a price of $6.21 per share for total aggregate gross proceeds of approximately $6.5 million.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the market closes on Wednesday, May 6, 2020.

Omnicell, Inc. (NASDAQ: OMCL), today announced that due to the public health impact of the novel coronavirus (COVID-19) pandemic and to protect the health and wellbeing of its employees, stockholders and the broader community, the Company will hold its 2020 Annual Meeting of Stockholders in a virtual meeting format only, via live audio webcast.

Portola Pharmaceuticals, Inc.® announced that on April 30, 2020, the Compensation Committee of the Board of Directors approved, effective as of April 30, 2020, the grant to five new employees of inducement stock options to purchase an aggregate of 10,700 shares of common stock, and awards of 5,350 restricted stock units in the aggregate.

3M announced that it has completed the sale of substantially all of its drug delivery business to an affiliate of Altaris Capital Partners, LLC., for approximately $650 million in total consideration, including cash, an interest-bearing security, and a 17 percent noncontrolling interest in the new company, Kindeva Drug Delivery, that will operate the business.

ProBioGen AG, a premier, Berlin-based CDMO for developing and manufacturing complex therapeutic glycoproteins today announced that Dr. Lutz Hilbrich, an experienced biotech executive, has been named Chief Executive Officer, effective June 1, 2020

Working with an international team of experts from universities on the forefront of air quality monitoring research, RESET® will be releasing a new air quality standard aimed at providing a framework for qualifying airborne particulate sensors - specifically optical particle counters - used for indoor and outdoor air quality monitoring.

Recognition as a recipient of the CRO Leadership Awards reflects Catalyst’s growing customer base, expanding solutions and continuation of its flexible, high quality service delivery model.